Clinical Research Unit, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Section of Nursing, Aarhus University, Copenhagen, Denmark.
J Clin Nurs. 2019 Jul;28(13-14):2443-2461. doi: 10.1111/jocn.14785. Epub 2019 Mar 3.
To examine cancer patients' perceptions of factors that may influence their decisions on participating in phase I-III clinical drug trials.
The number of cancer participants in clinical drug trials has increased rapidly in Denmark in recent years. The rights, safety and well-being of patients considering participation are protected by the international, ethical and scientific principles. A meta-synthesis was conducted to enable health professionals to support cancer patients who are considering trial participation in accordance with the above principles.
Meta-synthesis.
A qualitative meta-synthesis, as described by Sandelowski and Barroso, was conducted based on a literature search in PubMed, CINAHL, EMBASE and PsycINFO. Nine reports were found eligible and were included. The PRISMA checklist was used.
A framework was developed, and patients' perceptions of the factors influencing their decisions were identified, namely patients' perceptions of their relatives, the physician, the hope of therapeutic benefit, altruism, having other options and living with cancer.
This study shows that cancer patients' decisions on participation in clinical drug trials are influenced by their perceptions of trust towards the physician, their relatives' attitudes and the consequences participation might have for their families. Patients are motivated to participate due to the hope of therapeutic benefit and for altruistic reasons. The factors influencing their decisions to participate include a cost-benefit consideration, which in turn may be subject to the patient's perception of having other options available besides participation. This may be related to the patient's attitude towards living with cancer, and the decision can be a way of trying to cope with the psychological aspects of living with cancer.
The results of this meta-synthesis offer insight into patients' perceptions of what may influence their decisions, and they enable health professionals to support patients making such decisions.
调查癌症患者对可能影响其参与 I 期至 III 期临床药物试验决策的因素的看法。
近年来,丹麦癌症患者参与临床药物试验的人数迅速增加。国际、伦理和科学原则保护考虑参与试验的患者的权利、安全和福祉。进行元综合是为了使卫生专业人员能够根据上述原则支持考虑参与试验的癌症患者。
元综合。
根据在 PubMed、CINAHL、EMBASE 和 PsycINFO 中进行的文献检索,进行了 Sandelowski 和 Barroso 描述的定性元综合。发现了 9 份符合条件的报告,并将其纳入。使用 PRISMA 清单。
制定了一个框架,并确定了影响患者决策的因素,即患者对其亲属、医生、治疗获益的希望、利他主义、有其他选择和与癌症共存的看法。
这项研究表明,癌症患者参与临床药物试验的决定受到他们对医生的信任、亲属的态度以及参与对家庭可能产生的后果的看法的影响。患者参与的动机是出于治疗获益的希望和利他主义的原因。影响他们参与决策的因素包括成本效益考虑,这反过来又可能受到患者对除参与之外还有其他选择的看法的影响。这可能与患者对与癌症共存的态度有关,而做出决定可能是一种试图应对与癌症共存的心理方面的方式。
本次元综合的结果提供了对患者对可能影响其决策的因素的看法的深入了解,并使卫生专业人员能够支持患者做出这些决策。